Indegene Partners with IISc and Ignite for Scientific Discovery in India

On June 12, 2024, Indegene Limited informed the stock exchanges that the company’s Section 8 not-for-profit foundation, Ignite Life Science Foundation (ILSF) and the Indian Institute of Science (IISc), partnered with Indegene to advance scientific discoveries in India.

Professor G. Mugesh from IISc, Bengaluru, expressed excitement about collaborating with Indegene and Ignite and appreciated their support. He sees this collaboration as a significant advancement for scientific discoveries in India and foresees it paving the way for accelerating scientific innovation in the future.

Professor Mugesh’s research focuses on “Small Molecule GPX Mimetics for Preventing Cardiovascular and Neurodegenerative Diseases.” Indegene and Ignite LSF have supported IISc by supplying a new multimode plate reader equipped with absorbance, fluorescence, and luminescence capabilities crucial for laboratory experiments in this field.

Regarding the necessity for advancing scientific discoveries in the cardiovascular and neurodegenerative diseases space, the company stated that cardiovascular and neurodegenerative diseases pose significant health challenges globally, affecting millions of individuals. As the global population ages, the prevalence of these diseases is expected to rise. The World Health Organization (WHO) predicts that neurodegenerative diseases will become the 2nd leading cause of death worldwide by 2040. Effective treatment and preventive solutions are urgently needed to mitigate the increasing burden on public health.

At IISc, the focus lies on developing innovative small molecules and nanomaterial-based functional mimetics of GPX4, targeting ferroptosis inhibition to offer protective mechanisms against these diseases. Given the lab’s role in drug discovery, extensive screening of molecules is imperative to identify lead compounds, necessitating the utilisation of multiple screening systems.

The member of Ignite’s Scientific Advisory Board and President and a Director on the board of GangaGen Biotechnologies Private Ltd, Bengaluru, Dr T. S. Balganesh, said, “The multiplate reader will increase throughput and accelerate experiments. Rich biological data can drive the generation of new insights and open up fresh areas for investigation.”

“As an organisation founded to enable future-ready healthcare, we are committed to being the catalysts for the change we need in the communities we work in. We are delighted to support IISc and Ignite to help advance scientific innovation,” said Manish Gupta, Chairman and CEO of Indegene Limited.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.